Blog

//Blog

CytoReason uses AI to personalize #drugs, opening the door to #cancer treatments

STEWART ROGERS | APRIL 16, 2018 8:30 AM Image Credit: CytoReason   The first question most people have when talking about #artificialIntelligence is if it will help us or harm us. But in the health industry, the answer to that question is clear. Whether it is being used to identify patients at risk or interrogate #X-rays and scans to aid in [...]

By | 2018-04-24T11:57:15+00:00 April 24th, 2018|Blog|Comments Off on CytoReason uses AI to personalize #drugs, opening the door to #cancer treatments

Spotlight On Israel: Market Challenges Stunting Biopharma Growth

23 Apr 2018 | Lucie Ellis Executive Summary Scrip investigates the big issues Israel's #biopharma sector need to overcome in order to maintain momentum and achieve sustainable success. AHARON AHARON, CEO OF THE ISRAEL INNOVATION AUTHORITY. Source: Israel Innovation Authority In its 70th anniversary year, Israel can rightly celebrate the boom in its high-tech sector over the last [...]

By | 2018-04-24T11:57:16+00:00 April 24th, 2018|Blog, PR|Comments Off on Spotlight On Israel: Market Challenges Stunting Biopharma Growth

Healthy.io Brings Smartphone Urine Tests to U.S. Homes

The Israel-based startup partnered with the American National Kidney Foundation and Pennsylvania-based Geisinger Health System to offer its testing kits to U.S. patients Lilach Baumer | 19:26 15.04.18 The American National Kidney Foundation and Pennsylvania-based Geisinger Health System have partnered with Israel-based startup Healthy.io to enable smartphone-based urine tests at home. On Monday, the three will [...]

By | 2018-04-16T12:56:29+00:00 April 16th, 2018|Blog|Comments Off on Healthy.io Brings Smartphone Urine Tests to U.S. Homes

Mylan buys rights to Israel-developed Multiple Sclerosis treatment

MS drug developed by Mapi Pharma requires a once-monthly injection instead of 3 times a week By TOI STAFF 11 April 2018, 12:19 am | Times New Israel Mylan already sells a generic version of Teva Pharmaceuticals’ widely-used MS treatment, Copaxone. But, if GA Depot successfully completes its Phase III clinical trials, it will be formidable competition [...]

By | 2018-04-12T15:01:24+00:00 April 12th, 2018|Blog|Comments Off on Mylan buys rights to Israel-developed Multiple Sclerosis treatment

Medtronic Buys Medical Visualization Company Visionsense for $65 Million

The medical device developer intends to integrate Israel-based Visionsense's operations into its own activities Meir Orbach | 10:16 10.04.18 | Calcalistech Medical device maker Medtronic PLC is buying Israel-based medical visualization company Visionsense Ltd. for $65 million, two people familiar with the matter told Calcalist on condition of anonymity. Visionsense will receive an upfront payment of [...]

By | 2018-04-12T10:08:51+00:00 April 12th, 2018|Blog|Comments Off on Medtronic Buys Medical Visualization Company Visionsense for $65 Million

Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing

EMERGING ISRAELI BIOPHARMA FLIES FLAG FOR EX-BMS CANCER THERAPY by Phil Taylor | Apr 10, 2018 9:57am | FierceBiotech Israeli biotech Ayala Pharmaceuticals, founded last year as a development vehicle for two of Bristol-Myers Squibb’s cancer candidates, has raised $17 million in a series A financing. The new company licensed rights to BMS’s gamma secretase inhibitor BMS-906024 in December, [...]

By | 2018-04-12T10:06:08+00:00 April 11th, 2018|Blog|Comments Off on Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing

MedImmune to Develop Compugen Immuno-Oncology Antibodies

April 2, 2018 | GEN News Highlights AstraZeneca’s #MedImmune subsidiary has agreed to exclusively license and develop #bispecific and multispecific #immuno-oncology antibody products from Compugen’s pipeline, through a collaboration that #Compugen said today could generate for it up to $210 million-plus. Compugen said it will grant MedImmune an exclusive license to develop bispecific and multispecific antibody products [...]

By | 2018-04-03T10:16:27+00:00 April 3rd, 2018|Blog|Comments Off on MedImmune to Develop Compugen Immuno-Oncology Antibodies

InSight #Biopharmaceuticals Buys #Cancer #Treatment Company CureTech

As part of the deal, InSight commits to help develop CureTech’s lead product, which is currently in advanced #clinical trials Lilach Baumer17:4228.03.18 Pharmaceutical company InSight Biopharmaceuticals Ltd. has signed a deal to acquire cancer treatment company CureTech Ltd. The announcement was made Wednesday by Clal Biotechnology Industries, which holds 53% of CureTech’s shares. As [...]

By | 2018-03-29T17:21:24+00:00 March 29th, 2018|Blog|Comments Off on InSight #Biopharmaceuticals Buys #Cancer #Treatment Company CureTech

Cabinet approves NIS 922m for digital health project

The ambitious plan is designed to make Israel a digital health power and improve the health of its residents, and of the entire world. Israel's cabinet today approved a NIS 922 million budget for a national digital health project. The plan includes a number of elements, the combination of which is designed to make [...]

By | 2018-03-26T11:17:10+00:00 March 26th, 2018|Blog|Comments Off on Cabinet approves NIS 922m for digital health project

Google looks to take healthcare into the Cloud

MARCH 6, 2018 BY FINK DENSFORD Google (NSDQ:GOOG) is taking its Cloud services into the field of healthcare as it aims to enable data sharing and collaboration between providers and patients, according to a recent blog post from the tech giant. The company said it recently launched the Cloud Healthcare API service to address interoperability issues in [...]

By | 2018-03-07T13:33:06+00:00 March 7th, 2018|Blog|Comments Off on Google looks to take healthcare into the Cloud